期刊文献+

甲钴胺联合凯时治疗糖尿病周围神经病变效果观察 被引量:2

Effect of Mecobalamin combined with Alprostadil in the treatment of diabetic peripheral neuropathy
下载PDF
导出
摘要 目的:观察甲钴胺联合凯时治疗糖尿病周围神经病变的临床效果,以评价其临床价值。方法:糖尿病周围神经病变患者82例随机分为治疗组和对照组各41例,治疗组给予甲钴胺联合凯时治疗;对照组给予维生素B12治疗。比较两组治疗前、后Semmes-Weinstein单丝(5.07/10g)检查、MNSI(Michigan Neuropathy Screening Instrument),神经传导速度结果。结果:治疗组治疗后Semmes-Weinstein单丝(5.07/10g)检查、MNSI(Michigan Neuropathy Screening Instrument),神经传导速度结果均较治疗前明显改善,且优于对照组,差异均有统计学意义。结论:甲钴胺联合凯时治疗糖尿病周围神经病变疗效显著,值得临床推广应用。 Objective:To observe the effect of Mecobalamin combined with Alprostadil in the treatment of diabetic peripheral neuropathy and to evaluate its clinical value.Methods:82 patients with diabetic peripheral neuropathy were randomly divided into treatment group and control group averagely.The treatment group was administered Mecobalamin combined with Alprostadil(PGE1) for four weeks,at the same time,the control group received vitamin B12.Semmes-Weinstein monofilament exam,Michigan Neuropathy Screening Instrument(MNSI) and nerve conduction velocity results in the two groups were compared before and after treatment.Results:Semmes-Weinstein monofilament exam,Michigan Neuropathy Screening Instrument(MNSI) and nerve conduction velocity results after 4-week treatment were all improved in treatment group than those before treatment and those in control group.Conclusion:Mecobalamin combined with Alprostadil in the treatment of diabetic peripheral neuropathy is effective and deserves to the clinical popularization and application.
作者 王玉梅 宋宏
出处 《黑龙江医药科学》 2012年第2期25-26,共2页 Heilongjiang Medicine and Pharmacy
关键词 糖尿病周围神经病变 甲钴胺 凯时 diabetic peripheral neuropathy Mecobalamin Alprostadil
  • 相关文献

参考文献4

  • 1廖二元 超楚生.内分泌学[M].北京:人民卫生出版社,2002,1453-5..
  • 2侯瑞芳,汤正义,宁光.糖尿病周围神经病变的检查方法及其诊断效率[J].国际内分泌代谢杂志,2006,26(4):270-272. 被引量:42
  • 3Brownlee M. Biochemistry and molecular cell biology of diabetic complications[J]. Nature,2004,414:813.
  • 4Kashyap AS, Anand KP, Kashyap S, et al. Perpheral neurophathy [J]. Lancet, 2004,364:641 - 665.

二级参考文献23

  • 1Bril V.Current treatment of diabetic neuropathy.Can J Diabetes Care,2002,24 (Suppl 2):67-75.
  • 2Forouzandeh F,Aziz Ahari A,Abolhasani F,et al.Comparison of different screening tests for detecting diabetic foot neuropathy.Acta Neurol Scand,2005,112:409-413.
  • 3Meijer JW,Bosma E,Lefrandt JD,et al.Clinical diagnosis of diabetic polyneuropathy with the diabetic neuropathy symptom and diabetic neuropathy examination scores.Diabetes Care,2003,26:697-701.
  • 4Bril V,Perkins BA.Validation of the Toronto clinical scoring system for diabetic polyneuropathy.Diabetes Care,2002,25:2048-2052.
  • 5Quattrini C,Jeziorska M,Malik RA,et al.Small fiber neuropathy in diabetes:chnical consequence and assessment.Int J Low Extrem Wounds,2004,3:16-21.
  • 6Bansal V,Kalita J,Misra UK.Diabetic neuropathy.Postgrad Med J,2006,82:95-100.
  • 7Miranda-Palma B,Basu S,Mizel MD,et al.The monofilament as the gold standard for foot ulcer risk screening:a reappraisal (Abstract).Diabetes,2003,52 (Suppl 1):A63.
  • 8Kamei N,Yamane K,Nakanishi S,et al.Effectiveness of Semmes-Weinstein monofilament examination for diabetic peripheral neuropathy screening.J Diabetes Complications,2005,19:47-53.
  • 9Herman WH,Kennedy L.Underdiagnosis of peripheral neuropathy in type 2 diabetes.Diabetes Care,2005,28:1480-1481.
  • 10Meijer JW,Smit A J,Lefrandt JD,et al.Back to basics in diagnosing diabetic polyneuropathy with the tuning fork! Diabetes Care,2005,28:2201-2205.

共引文献55

同被引文献25

  • 1Chung SS, Ho EC, Lam KS, et al. Contribution of polyolpathway to diabetes-induced oxidative stress[J]. Am Soc Nephrol, 2003, 14(3) : S233- 236.
  • 2King RHM. The role of glycation in the pathogenesis of diabetic polyneuropathy[J]. Clim Pathol Mol Pathol, 2001,54 (6) : 400-408.
  • 3Gruber K, Puffer B, Krautler B. Vitamin B12-derivatives-enzyme cofactors and ligands of proteins and nucleic acids[J]. Chem Soc Rev, 2011, 40(8) :4346-4363.
  • 4Zhang YF, Ning G. Mecobalamin[J]. Expert Opin Investig Drugs, 2008,17(6) :953-64.
  • 5Harding SV, Rideout TC, Jones PJ. Evidence for using alpha-lipoic acid in reducing lipoprotein and inflammatory related atherosclerotic risk[J]. J Diet Suppl, 2012, 9(2):116-127.
  • 6Goraca A, Huk-Kolega H, Piechota A, et al. Lipoic acid -biological activity and therapeutic potential[J]. Pharmacol Rep, 2011,63(4) :849-858.
  • 7Tiaka EK, Papanas N, Manolakis AC, et al. The role of hyperbaric oxygen in the treatment of diabetic foot ulcers[J]. Angiology, 2012, 63 (4) :302-314.
  • 8Liu ZJ, Velazquez OC. Hyperoxia, endothelial progenitor cell mobilization, and diabetic wound healing[J]. Antioxid Redox Signal, 2008,10(11):1869-1882.
  • 9McMillan G, Glover M. The clinical and economic potential of hyperbaric oxygen therapy in the treatment of diabetic ulceration and other conditions[J]. Int J Low Extrem Wounds, 2007, 6(3): 130-138.
  • 10陈玉凤,沈育芬,张会娟.果糖二磷酸钠联合α-硫辛酸治疗糖尿病周围神经病变临床效果观察[J].中国综合临床,2010,26(3):292-294. 被引量:5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部